A population-based cohort study led by Yunha Noh, Pharm D, PhD, assessed the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and gastroesophageal reflux disease (GERD) in type 2 diabetes patients. The study found a 27% increased risk of GERD in those using GLP-1 RAs compared to sodium–glucose cotransporter-2 inhibitors. Following 24,708 GLP-1 RA users and 89,096 SGLT-2 users, the results indicated a higher incidence of GERD and related complications, especially among smokers and obese patients, highlighting the need for careful consideration of gastrointestinal risks by clinicians.
Source: Annals of Internal Medicine